Conclusion: DOP could improve obesity-associated IR and abnormal lipid metabolism through its activities on PPAR-γ, and may serve as a potential therapeutic agent for obesity-associated insulin resistance and lipid metabolism disorder. The gene discussed is PPARG; the disease is obesity due to melanocortin 4 receptor deficiency.